Literature DB >> 8314234

Detection of Epstein-Barr virus nucleic acid sequences and protein in nodal T-cell lymphomas: relation between latent membrane protein-1 positivity and clinical course.

P C De Bruin1, N M Jiwa, P Van der Valk, P Van Heerde, R Gordijn, G J Ossenkoppele, J M Walboomers, C J Meijer.   

Abstract

Forty-six nodal T-cell lymphomas, classified according to the updated Kiel classification, were investigated for the presence of Epstein-Barr virus (EBV) DNA by polymerase chain reaction (PCR), EBER 1 and 2 (EBER 1/2) and latent membrane protein-1 (LMP-1) expression. A combination of RNA in situ hybridization and immunohistochemistry was used to establish the phenotype of the Epstein-Barr virus harbouring cells. In 21 of 45 cases Epstein-Barr virus DNA sequences could be detected with the polymerase chain reaction. In 15 cases (14 of 21 EBV PCR positive cases), EBER 1/2 positive cells could be demonstrated. As judged by morphology, EBER 1/2 expression was found in nonneoplastic and neoplastic lymphoid cells. Double staining revealed that more than 80% of the EBER 1/2 harbouring cells, lacked B-, T- or histiocytic markers, suggesting down regulation of T- and B-cell markers by Epstein-Barr virus. In eight of 15 cases some EBER 1/2 positive T-cells (CD3, CD45RO, CD43) morphologically resembling tumour cells were found. In nine of 14 cases tested EBER 1/2 positive non-neoplastic B-cells (CD20) were seen. Based on in situ hybridization results, four patterns of EBER 1/2 positive cells were found, i.e. single cells (< 1 per medium power field (mpf), n = 3), scattered (1-25/mpf, n = 4), clustered (26-100/mpf, n = 5) and diffuse (> 100/mpf, n = 3). In eight of 15 cases a clustered or diffuse pattern of EBER 1/2 positive cells was found and these lymphomas were therefore considered to be strongly associated with Epstein-Barr virus. In these lymphomas LMP-1 expression was found to be associated with an aggressive clinical course and hepatosplenomegaly.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8314234     DOI: 10.1111/j.1365-2559.1993.tb01236.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  5 in total

1.  A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies.

Authors:  Susan P Perrine; Olivier Hermine; Trudy Small; Felipe Suarez; Richard O'Reilly; Farid Boulad; Joyce Fingeroth; Melissa Askin; Arthur Levy; Steven J Mentzer; Massimo Di Nicola; Alessandro M Gianni; Christoph Klein; Steven Horwitz; Douglas V Faller
Journal:  Blood       Date:  2006-11-21       Impact factor: 22.113

2.  Expression of epstein-barr virus encoded nuclear antigen 1 in benign and malignant tissues harbouring EBV.

Authors:  J J Oudejans; D F Dukers; N M Jiwa; A J van den Brule; F A Grässer; P C de Bruin; A Horstman; W Vos; J van Gorp; J M Middeldorp; C J Meijer
Journal:  J Clin Pathol       Date:  1996-11       Impact factor: 3.411

3.  Immunohistochemical demonstration of different latent membrane protein-1 epitopes of Epstein-Barr virus in lymphoproliferative diseases.

Authors:  N M Jiwa; J J Oudejans; D F Dukers; W Vos; A Horstman; P van der Valk; J M Middledorp; J M Walboomers; C J Meijer
Journal:  J Clin Pathol       Date:  1995-05       Impact factor: 3.411

4.  Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas.

Authors:  Bradley M Haverkos; Ying Huang; Alejandro Gru; Preeti Pancholi; Aharon G Freud; Anjali Mishra; Amy S Ruppert; Robert A Baiocchi; Pierluigi Porcu
Journal:  Int J Cancer       Date:  2017-04-15       Impact factor: 7.396

Review 5.  The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment.

Authors:  A A Gru; B H Haverkos; A G Freud; J Hastings; N B Nowacki; C Barrionuevo; C E Vigil; R Rochford; Y Natkunam; R A Baiocchi; P Porcu
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.